Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of BBP-711 in healthy adults
NCT04876924Phase 1Completed
- Sponsor
- BridgeBio Pharma
- Start
- Apr 2021
- Primary completion
- Feb 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BBP-711 in Primary Hyperoxaluria Type 1 (PH1) (6 arms), sponsored by BridgeBio Pharma. Primary endpoint: Safety and Tolerability. Started Apr 2021; status: completed.
02
Drugs
BBP-711
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Beyond the preview
Go deeper on NCT04876924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04876924.